Monopar Therapeutics (NASDAQ:MNPR) Receives Hold Rating from Jones Trading

Jones Trading reiterated their hold rating on shares of Monopar Therapeutics (NASDAQ:MNPR - Free Report) in a research note published on Wednesday morning, Marketbeat reports.

A number of other research firms have also recently weighed in on MNPR. Piper Sandler restated an "overweight" rating and issued a $76.00 price target on shares of Monopar Therapeutics in a report on Wednesday, March 19th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $44.00.

Monopar Therapeutics Stock Performance

Shares of NASDAQ:MNPR traded down $2.56 on Wednesday, hitting $27.44. 12,720 shares of the company's stock were exchanged, compared to its average volume of 358,620. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30. The firm's 50-day moving average is $38.29 and its 200 day moving average is $25.18. The company has a market capitalization of $167.74 million, a PE ratio of -13.93 and a beta of 1.01.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($2.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($1.87). On average, analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Activity at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total value of $1,166,690.00. Following the completion of the sale, the insider now directly owns 822,255 shares in the company, valued at approximately $28,778,925. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 34.90% of the company's stock.

Institutional Trading of Monopar Therapeutics

Institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. purchased a new position in shares of Monopar Therapeutics in the 4th quarter worth about $45,000. Geode Capital Management LLC lifted its position in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock valued at $849,000 after buying an additional 24,530 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Monopar Therapeutics in the fourth quarter worth $2,861,000. Point72 Asset Management L.P. purchased a new position in shares of Monopar Therapeutics in the 4th quarter valued at $3,694,000. Finally, RA Capital Management L.P. purchased a new stake in Monopar Therapeutics during the 4th quarter worth $11,247,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.